Pediatric bone marrow transplantation—also called hematopoietic stem-cell transplantation, or HSCT—may be considered for selected children with particular cancers, bone-marrow failure disorders, immune conditions, inherited blood disorders or metabolic diseases. A diagnosis alone does not show that a child needs transplant.
What is pediatric bone marrow transplantation?
Blood-forming stem cells produce red cells, white cells and platelets. HSCT gives stem cells after a conditioning regimen intended to prepare the child for the planned transplant. The cells may come from the child or from a separately assessed donor.
‘Bone marrow transplant’ is often used as an umbrella term, although stem cells may be collected from marrow, peripheral blood or another clinically appropriate source. The transplant team defines the source and procedure.
Autologous and allogeneic transplantation
An autologous transplant uses the child’s own collected cells. They are collected and stored, and later returned after conditioning or high-dose treatment. A donor is not used.
An allogeneic transplant uses cells from another person. The team may assess a matched related donor, a partially matched haploidentical donor, or a matched unrelated donor. Each route requires a separate clinical and safeguarding process.
Understanding donor and HLA pathways
A family relationship does not automatically make someone a suitable donor. HLA compatibility, donor health, infection screening, consent, safeguarding and the proposed cell source all require hospital-led assessment.
- Matched related allogeneic: an assessed related donor has a suitable HLA match.
- Haploidentical: a partially matched related donor may be evaluated when a fully matched option is unavailable or unsuitable.
- Matched unrelated donor (MUD): specialists may authorize a registry search for a suitably matched person who is not related to the child.
Which donor pathway may be evaluated?
Patient’s own cells
- Autologous may be evaluated
Suitable matched related donor
- Matched related allogeneic may be evaluated
Suitable partially matched donor
- Haploidentical may be evaluated
No suitable family donor
- A matched unrelated donor search may be considered
When a matched unrelated donor search is considered
If there is no suitable family donor, the transplant team may consider a registry search. The supplied Acıbadem material describes high-resolution HLA typing, a preliminary computerized search, and a formal search with confirmatory donor testing when specialists decide to proceed.
The source says searching may take months and gives a broad estimate extending from about three months to one year. This is source-specific planning information, not a guarantee. A potential match still requires confirmation, donor clearance and hospital approval.
Recipient and donor evaluation
The child’s evaluation may include confirmation of diagnosis and disease status, prior treatment and response, organ-function and infection assessment, blood tests, imaging, cardiac or respiratory assessment, and marrow, pathology, molecular or genetic reports when relevant.
A possible donor follows a separate evaluation. The hospital determines repeat HLA testing, health screening, collection safety and whether another donor should be considered.
Conditioning and stem-cell infusion
Conditioning uses medicines—and sometimes other treatment—to prepare for transplant. The regimen varies by diagnosis, pathway and the child’s condition. Stem-cell infusion is one stage in a longer treatment process.
Pediatric BMT Evaluation & Treatment Journey
- 01Medical records
- 02Pediatric specialist review
- 03Transplant pathway assessment
- 04Donor and HLA assessment if required
- 05Pre-transplant evaluation
- 06Conditioning
- 07Stem-cell infusion
- 08Engraftment and monitoring
- 09Discharge
- 10Outpatient follow-up
- 11Return home when clinically appropriate
Engraftment, infection, GVHD and chimerism monitoring
Engraftment means transplanted cells begin producing blood cells. The child may need blood-product support, infection treatment, nutrition and frequent laboratory monitoring. The supplied donor-based Acıbadem offers describe approximately 10–25 days to engraftment, but each child’s course differs.
After allogeneic transplant, teams monitor for graft-versus-host disease (GVHD), in which donor immune cells can affect the child’s tissues. Chimerism testing may assess the proportion of donor-derived blood-forming cells.
Discharge and recovery
Discharge depends on clinical stability, blood-count recovery, infection control, medicines and a safe follow-up plan. Outpatient assessments may remain frequent, while immune recovery can continue for months or longer.
Planning pediatric BMT abroad
- Maintain current local pediatric care while seeking international review.
- Wait for meaningful hospital feedback before non-refundable travel.
- Confirm guardian documents and who must accompany the child.
- Plan for admission and post-discharge monitoring that may last weeks or months.
- Budget for accommodation and living costs after discharge.
- Agree how follow-up will continue with the child’s local team.
The supplied offers describe stays measured in weeks and repeated outpatient assessment. These are estimates, not promises. Complications can extend treatment or stay, accommodation costs remain with the family where stated, and travel home requires specialist approval.
How pediatric BMT costs are clarified
Costs depend on transplant type, donor pathway or search, evaluations, conditioning, hospitalization, medicines, complications, additional treatment and length of stay. Current hospital costs should be confirmed after medical evaluation and selection of the appropriate transplant pathway.
The documents contain historical package prices, but these are not published as current or starting prices. MedTransplant may request a current plan and quotation, clarify charges and advocate for transparent costs without guaranteeing discounts or savings.
Questions parents can ask
- Why is HSCT being considered, and what alternatives remain?
- Which transplant type and cell source may be evaluated?
- How will a possible donor be assessed and protected?
- What complications are relevant to this pathway?
- What determines discharge and permission to travel home?
- What is included and excluded from the current written quotation?
How MedTransplant supports preliminary evaluation
A parent or legal guardian can submit available records through the existing Case Review. MedTransplant organizes the file, coordinates preliminary review, communicates requests for missing information and can help compare verified programs.
If Acıbadem Altunizade is selected as one potential pathway, its pediatric specialists make every diagnosis, donor, eligibility, treatment and acceptance decision. MedTransplant may coordinate the plan, quotation clarification, appointments, travel preparation and return communication.
Common questions
Frequently asked questions
What is pediatric bone marrow transplantation?
It provides blood-forming stem cells after conditioning. The cells may come from the child or an assessed donor.
What is the difference between autologous and allogeneic transplant?
Autologous uses the child’s own collected cells. Allogeneic uses donor cells and requires donor assessment.
Does my child need a donor?
Not for autologous transplant. Donor cells are required for allogeneic pathways; specialists decide which approach is appropriate.
Does the donor have to be a sibling?
No. A sibling may be evaluated, but related, haploidentical and unrelated pathways exist.
What does HLA matching mean?
HLA typing compares immune-system markers between the child and possible donors; it is more complex than blood-group matching.
What is a haploidentical donor?
A partially HLA-matched related donor. Family relationship alone does not establish suitability.
What if there is no matched family donor?
Specialists may consider another route, including an authorized unrelated-donor search.
How long can an unrelated donor search take?
The supplied Acıbadem source gives a broad estimate of roughly three months to one year. It is not guaranteed.
How long might my child remain in Türkiye?
The period depends on pathway, engraftment, complications and post-discharge monitoring. Travel home requires specialist approval.
What records should we submit?
A current specialist summary, diagnosis and pathology or marrow reports, treatment history, recent tests and any requested HLA results.
Does submission mean Acıbadem will accept my child?
No. Submission guarantees neither eligibility, donor suitability, acceptance nor transplant.
Can MedTransplant find a donor?
No. MedTransplant does not find, recruit, sell, broker or guarantee donors.
How much does pediatric BMT cost?
A current quotation requires evaluation and an identified pathway; testing, donor work-up, admission and complications all affect cost.
Who makes the final transplant decision?
The responsible pediatric transplant specialists.
Evidence base
References and further reading
Continue exploring
Related MedTransplant guides
CAR T-Cell Therapy at Acıbadem in Türkiye
Understand another specialist cellular-therapy pathway for selected hematologic malignancies.
Read guide